SIRPA and acute lymphoblastic leukemia: IgA2-mediated ADCP against T-ALL cell lines HSB-2, MOLT-13 and P12 and primary patient samples was significantly enhanced blocking the CD47/SIRPα axis through the genetic ablation of either CD47 or QPCTL, or by the use of a CD47 blocking antibody.